Tuberculosis resists the body's first-line defenses

Tuberculosis remains a major global threat, and scientists have long wanted to understand how the body fights the very earliest stages of infection. Mycobacterium tuberculosis (Mtb) is known to be a strong activator of innate immunity, the rapid, general-purpose defense the body mounts before specialized adaptive immunity kicks in. But whether that early response actually stops Mtb while the adaptive response is still forming has been unclear. Much previous work tested infection in specific pathogen-free (SPF) mouse models and used fairly large doses of bacteria, conditions that might hide any subtle effects of innate defense. To address that question, Russell E. Vance and collaborators took a different approach. They used ultra-low dose Mtb infections to mimic very small exposure events, co-housed C57BL/6 mice with “pet shop” mice to broadly prime the animals’ immune systems, and also tested what happens when the lung’s innate defenses are strongly activated in advance by infecting mice with Legionella pneumophila (Lp). The goal was simple: ask whether innate immunity, under several different realistic conditions, can stop Mtb before adaptive immunity arrives.

Across these varied models the results were clear and consistent. In ultra-low dose infections, the initial innate response failed to curb even minimal Mtb infectious doses, meaning the bacteria could establish and begin to replicate. Co-housing C57BL/6 mice with “pet shop” mice, a maneuver intended to broadly prime immunity by exposing animals to a wider range of microbes, did not protect animals: co-housed mice were as susceptible to Mtb infection as SPF mice. To more specifically activate innate defenses in the lung, researchers infected animals with Legionella pneumophila (Lp) before exposing them to Mtb. While innate immunity alone rapidly cleared large doses (>100,000 CFU) of Lp from the lung within a few days, pre-infection with Lp only modestly reduced Mtb colony-forming units (CFU) compared to mice infected with Mtb alone. The team also used single-cell RNA-sequencing on myeloid cells from mice infected with Mtb alone or primed with Lp. That analysis showed measurable changes in myeloid cell responses after Lp priming, but those changes had little effect on innate control of Mtb.

Taken together, these experiments argue that Mtb is unusually resistant to innate immune clearance. The bacterium can withstand a range of early inflammatory states and replicate even when the lung’s innate defenses are recently activated or when the host has been broadly exposed to other microbes. This resistance held true across very small infectious doses, after immune priming by co-housing, and despite measurable shifts in myeloid cell activity detected by single-cell RNA-sequencing. For researchers, the findings shift attention away from expecting innate immunity alone to stop Mtb and toward understanding how adaptive responses or other interventions can be mobilized to prevent early bacterial establishment. The study demonstrates the importance of testing infections under diverse, realistic conditions to reveal how pathogens like Mtb evade the body’s first-line defenses.